naperiglipron
Naperiglipron Trial Terminations Highlight Shifts in Oral GLP-1 Market
Eli Lilly stopped two Phase 2 trials of naperiglipron after minimal enrollment, citing strategic reasons. Development continues in obesity, but structural similarity to Pfizer’s failed compounds raises safety scrutiny.